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Abstract: This review is divided into two interconnected parts, namely a biological and a 
chemical one. The focus of the first part is on the biological background for constructing 
tissue-engineered vascular grafts to promote vascular healing. Various cell types, such as 
embryonic, mesenchymal and induced pluripotent stem cells, progenitor cells and 
endothelial- and smooth muscle cells will be discussed with respect to their specific 
markers. The in vitro and in vivo models and their potential to treat vascular diseases are 
also introduced. The chemical part focuses on strategies using either artificial or natural 
polymers for scaffold fabrication, including decellularized cardiovascular tissue. An 
overview will be given on scaffold fabrication including conventional methods and 
nanotechnologies. Special attention is given to 3D network formation via different 
chemical and physical cross-linking methods. In particular, electron beam treatment is 
introduced as a method to combine 3D network formation and surface modification. The 
review includes recently published scientific data and patents which have been registered 
within the last decade. 
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This review summarizes original articles and patents from the last decade dealing with artificial 
replacements for damaged vessels with respect to tissue engineering methods and thus reflects  
the rising interest in this specific subject (Figure 1A). The focus is on the cell types and their 
characterization as well as on the used in vitro and in vivo 3D models. For a fundamental review on 
articles and patents dealing with the underlying cause of atherosclerosis and its treatment using  
bypass surgery or angioplasty with and without stents, we recommend the review of Limbach and 
colleagues [1]. 
Autologous arterial and venous grafts are commonly used and are the ideal source for  
small-diameter bypass grafts. However, if the patient does not have blood vessels of adequate quality, 
e.g., as a result of previous operations or collateral diseases, artificial grafts represent a promising 
alternative. The cells should be available in abundant supply, preferably from the patient himself to 
avoid undesired immune reactions. Thus, primary differentiated cells such as endothelial or smooth 
muscle cells are a reasonably good option if available. Guided tissue regeneration with undifferentiated 
or differentiated stem cells with the respective plasticity might be the alternative. Due to the limited 
availability of primary tissue cells, stem cells are of major interest for usage in grafts to promote 
vascular healing. This is mirrored in the publications and patents of the last decade (Figure 1B,C). 
Stem cells can be divided into three major groups: pluripotent embryonic stem cell (ESCs), induced 
pluripotent stem cells (iPS) and adult stem cells (ASCs) of various plasticities. All groups share the 
ability of self-renewal, a major advantage compared to primary tissue cells, but they differ in their 
capacity to differentiate into the various tissue lineages. While ESCs and iPS are pluripotent, meaning 
they can differentiate into any cell type of the three germinal layers, ASCs are only multipotent, thus 
have a limited ability to differentiate towards several lineages only [2,3]. 
Embryonic stem cells were the prominent cell source in publications at the beginning of the decade 
but the numbers decreased when Takanashi and Yamanka described a method to induce pluripotency 
in somatic cells, creating the so called iPS [4,5]. Since iPS have a similar potency but cause fewer 
ethical problems and provide in addition the possibility for the future application of autologous cells, 
there is a rising interest in this specific cell type (Figure 1B,C). Interestingly the use of mesenchymal 
stem cells (MSCs) was not affected by the hype on iPS cells for future applications in regenerative 
medicine. MSCs, which belong to the group of adult stem cells, are multipotent and represent an 
interesting source for the use on vascular grafts since they can be differentiated in the desired cell 
types. Progenitor cells, such as endothelial progenitor cells (EPC) are unipotent, meaning they can 
only differentiate into one specific cell type, e.g., endothelial cell (EC). EPCs can be obtained from 
peripheral blood (PB-EPC), bone marrow (BM-EPC), umbilical cords (UC-EPC) and umbilical cord 
blood (UB-EPC) and named accordingly. According to the composition of blood vessels, primary 
endothelial cells and smooth muscle cells can be used as well in grafts to promote vascular healing. The 
isolation of ECs and SMCs is always accompanied with the destruction of the tissue (e.g., arteries and 
veins) and therefore limited in humans. In addition, the collectable amount of cells is low; thus, it is time 
consuming to get an appropriate amount of cells for vascular grafts. This might be the reason why the 
last mentioned cells types, although they have been used for quite some time, have never peaked but are 
still used on a regular basis (Figure 1B,C). 
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Figure 1. Publications and patents broaching the issue of vascular healing. (A) Publications 
(88) and patents (108) in the time period between 2003 and 2012 broaching the issue of 
vascular healing have been evaluated. The number of publications and patents is increasing 
after 2006 showing the growing interest in treating vascular diseases with stem cells  
and biomaterial. Blue: publications, green: patents; (B) Cell types for vascular healing 
approaches described in publications in the last decade. Embryonic stem cells were 
prominent in publications at the beginning of the decade. Their number decreased when in 
the iPS came up in the middle of the decade. Since iPS have a similar potency but cause 
less ethical problems and provide in addition the possibility for the future application of 
autologous cells, this was to be expected. Interestingly, the use of MSCs seems not to be 
affected by the development of induced pluripotent stem cell (iPS) cells. On the contrary, 
the use of this specific adult stem cell type is increasing. The reason for this might be the 
still unsolved risk of teratoma formation if endothelial cells (ECs) or IPS are used. ECs and 
smooth muscle cell (SMCs) have been described on a regular basis. The use of stem cells 
seems not to influence their utilization. Blue: EC, green: SMC, yellow: ESC, brown: MSC, 
orange: EPC, black: iPS, grey: other primary cells; (C) Cell types for vascular healing 
approaches described in patents during the last decade. The suggested used of the various 
cell types in patents follows the picture which can be seen in publications: The application 
of ECs is declining while the utilization of mesenchymal stem cell (MSC) which is the 
most prominent cell type. Blue: EC, green: SMC, yellow: ESC, brown: MSC, orange: EPC, 
black: iPS, grey: other primary cells. 
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Even though the best cell type for vascular grafts and other clinical applications is still unclear, 
more than 3000 clinical trials have been applied so far utilizing stem cells to treat various diseases [6]. 
Most of these treatments are still in phase I or phase II, and most of them focus on cancer (>2500), and 
not tissue engineering but nevertheless they provide some new insight and improvement for 
regenerative approaches. However, stem cells seem to have only short-term positive effects within 
their tissues and data on long-term benefits are missing for nearly all stem cell therapies. The stem 
cells seem to have only paracrine effects on the neighboring progenitors and somatic cells, and are lost 
within weeks of the application, presumably via apoptosis [7]. This is the polar opposite of what was 
expected, namely that stem cells will repair the damaged tissue or organ by differentiating into the 
cells which form and be functional in these tissues and organs. However, how to stimulate and induce 
stem cells to achieve the desired differentiation and/or repair the tissue seemingly cannot currently be 
pinned down. Therefore, addressing key molecules which regulate and determine stem cell fate is vital 
to improve above mentioned poor knowledge on what happens in tissue regeneration approaches with 
these cells and thus will be summarized and discussed in this review. 
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2. Stem Cells for Vascular Grafts 
The focus of the chapter is the characterization of various stem cell types differentiated towards 
endothelial and/or smooth muscle cells. For the characterization of the undifferentiated stem cells with 
their specific markers, the review of Calloni and coworkers is recommended [8]. 
2.1. Embryonic Stem Cells 
Embryonic stem cells are derived from the inner cell mass of blastocysts, which subsequently forms 
the embryo. As already mentioned, the pluripotency of these cells is their major advantage. However, 
this advantage is coupled with several disadvantages, such as ethical problems, due to the cell source 
and teratoma formation due to the fact that all cells will never undergo the induced differentiation 
process. In the past, most ESCs and embryonic germ cells were derived from human and mouse 
embryos. They have been characterized thoroughly defining a well defined set of specific markers.  
For a review on the marker of undifferentiated ESCs or the developmentally distinct and different 
markers of embryonic germ cells, the publications of Calloni [8] and Shamblott [9] are recommended. 
Recently, ESCs from mouse, human and rabbit have been used to construct tissue-engineered blood 
vessels (TEBV) or tissue-engineered vascular grafts (TEVG). To do so, the ESCs have been 
differentiated towards endothelial cells or smooth muscle cells by several groups. 
2.1.1. Endothelial Cell and Smooth Muscle Cell Markers Expressed in Differentiated ESCs 
To obtain cells for synthetic grafts promoting vascular healing, the ESCs have to be differentiated 
towards the desired lineages, namely ECs and SMCs. Subsequently, the cells have to be analyzed  
due to their expression pattern of EC and SMC marker. Depending on the strategy used, which is 
defined by differentiation media and the culture model, the groups achieved different results. Three 
representative strategies and their results are introduced here [10–12]. The three groups agreed on the 
EC marker PECAM-1 and the smooth muscle marker aSMA as key marker. Nakagami and colleagues 
showed that differentiated ESCs seeded on matrigel additionally secreted the growth factors VEGF, 
bFGF, HGF, TGF-β and Ang-1 [11]. The group of Ferreira cultured hESCs in EGM-2 medium  
with either the addition of VEGF-A165 or PDGF-BB and showed that these differentiated cells either 
expressed the EC markers PECAM-1, KDR/Flk-1, VE-cadherin, vWF or the SMC markers aSMA, SM 
myosin HC and calponin, respectively [12]. The influence of pulsatile flow with additional VEGF 
investigated by Huang resulted in an EC phenotype, while the lack of VEGF under the same 
conditions resulted in SMC phenotype [10]. In summary, the groups agree on VEGF as the major 
factor during both lineage commitments independent on the cell culture system while using ESCs as 
cell source. 
2.1.2. Embryonic Stem Cells for in Vitro 3D Culture Models 
To transfer a two-dimensional model into a three-dimensional model, two major strategies are 
pursed. In order to grow differentiated cells in gelatinous protein mixture, matrigel is the most 
commonly used material. It is used to investigate sprouting as a first step towards the formation of 
capillaries or the application of shear stress during flow to improve endothelial differentiation. An 
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example of the former is the publication of Nakagami, whereas Huang used differentiation from 
murine embryonic stem (ES) cells to vascular wall cells by mechanical stress loading in microporous 
tubes made of segmented polyurethane [10,11]. The oriented cells exhibited endothelial-like 
appearance and showed orientation into the direction of flow. Abilez and colleagues used a 
combination of both techniques and investigated the influence of pulsatile flow on undifferentiated 
mESC in a three-dimensional matrigel [13]. They were able to show that the cells constrained to the 
wells of the culture system, moved in unison with the applied flows, and were not washed downstream 
due to the additional application of the matrigel. Obviously this has to be repeated with the 
differentiated cells for further use. 
2.1.3. Embryonic Stem Cells for Vascular Grafts in Animal Models 
The major animal model to investigate the potential of ESCs for vascular healing is the mouse. In 
this model, xenotransplantation using ESCs of other origin is also common. Large animal models such 
as pigs, dogs, and sheep are used as well. The focus of these experiments is cell recruitment and the ESCs’ 
fate in these animals. Next to the above-mentioned molecular studies on the expression patterns of  
specific EC and SMC markers, these investigations include mainly histological and immunohistochemical 
experiments. Ferreira and colleagues confirmed the vascular potential of hESCs by implanting these cells 
grown on matrigel into mice, which resulted in the formation of a microvasculature [12]. Xiong and 
co-workers cultured hESCs-derived ECs and SMCs in a 3D fibrin gel and transplanted the graft into a 
myocardium infarction site of pigs and observed ventricular remodeling [14]. Shen and colleagues 
differentiated rabbit ESCs towards SMCs [15]. They transplanted a seeded PGA-scaffold into mice 
and showed the lining of endothelial cells on the lumimal surface and the presence of SMC and 
collagen in the wall. 
2.1.4. Patents on Embryonic Stem Cells for Vascular Grafts 
Interestingly, the current major focus of ESCs in patents is not the use of these cells in tissue 
engineering but the production of an extracellular matrix to promote wound healing and  
thus inhibit scarring. A typical example is the patent of McDevitt who developed a decellularized 
scaffold from embryonic stem cells to promote vascular healing [16]. Similarly, Yeryemyeyev 
produced a cardiomyocyte-matrix with the help of hESCs grown in defined medium to produce an 
extracellular matrix [17]. Nevertheless, tissue engineering for vascular organogenesis has also been 
patented by Hayashi for cultured ESCs or embryonic stem cell-derived embryoid bodies on growth 
factor-reduced matrigel [18].  
2.2. Induced Pluripotent Stem Cells 
In 2006, Takahashi and Yamanaka induced pluripotency in mouse embryonic and adult fibroblasts 
via viral introduction of the transcription factors Oct3/4, Sox2, c-Myc and Klf-4 [4,5]. They named the 
resulting cells “induced pluripotent stem cells”, iPS. The obtained cells showed ESC morphology and 
expressed typical ESC markers. When injected into blastocytes the iPS were incorporated into the 
development of the embryo. Injection into mice subcutaneous resulted in iPS derived tumors which 
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contained cells from all three germ layers. Wernig and colleagues could show that iPS are similar but 
not identical to ESC regarding methylation and chromatin state [19]. The iPS were able to form live 
late-term murine embryos. Yu and colleagues induced pluripotency and an ESC phenotype in human 
somatic fibroblasts characterized via screening of specific genes and surfaces markers and 
differentiation into all germ layers [20]. With application of nonintegrating adenoviruses transiently 
expressing the stem cell factors Oct3/4, Sox2, Klf4, and c-Myc the induction of pluripotency  
via potentially carcinogenic retroviruses was overcome [21]. However, the potential for tumor formation 
also originates from the pluripotency inducing four transcription factors. Several approaches have been 
conducted to reduce the number of necessary transcription factors. Kim and co-workers saw that murine 
ASCs expressed higher endogenous levels of Sox2 and c-Myc and therefore conducted the pluripotency 
induction only using the factors Oct3/4, and c-Myc or Klf4 [22,23]. The patented invention of Yamanaka 
disclosed similar methods inducing pluripotency in mammalian cells using the factors Oct3/4 or Nanog, 
introduced by viral vectors or nucleic acids encoding the latter two factors [24]. In the meantime, iPS 
induced with two factors (2F; Oct3/4 and Sox2) and even with only 1F (Oct3/4) have been produced 
where the amount of necessary factors is dependent on the cells source, progenitor cells or even stem 
cells, which need fewer transcription factors for the reprogramming process. 
Induced Pluripotent Stem Cells for Vascular Grafts 
Choi and colleagues reprogrammed human iPS cell lines from fibroblasts of different origin  
with Oct3/4, Sox2, Nanog and Lin26 [25]. In a co-culture system with murine bone marrow stromal 
cells they characterized the iPS for their differentiation potential and showed that the cells can 
differentiate into CD34/CD43 positive hematopoietic progenitor cells and ECs (PECAM-1 positive and 
CD43 negative). The treatment of limb ischemia was investigated by Lian and colleagues using 
comparison studies of the survival rate and differentiation potential of BM-MSC and human  
iPS-cell-derived MSCs [26]. The MSCs and iPS-derived cells were transplanted into mice and both cell 
types attenuated the ischemia. Both cell types promoted vascular and smooth muscle regeneration, 
with the positive effects of iPS-derived cells being the stronger one. Hibino and colleagues 
differentiated mouse iPS and produced a cell sheet as tissue-engineered vascular graft using 
temperature-responsive dishes [27]. They seeded the cells onto a biodegradable scaffold composed of 
polyglycolic acid-poly-L-lactide and poly(L-lactide-co-ε-caprolactone) and implanted it as interposition 
grafts into the inferior vena cava of mice. The cells expressed EC markers and histological 
investigations showed endothelialization and an inner SMC layer. The seeded iPS cells exerted a 
paracrine effect to induce neotissue formation in the acute phase and were lost over time. 
2.3. Mesenchymal Stem Cells 
Mesenchymal stem cells belong to the group of adult stem cells which are multipotent. They 
represent an increasingly investigated cell source for the use on vascular grafts (Figure 1B). These 
cells can be isolated from several tissues including wisdom teeth, peripheral blood, neonatal tissues 
(specific parts of the placenta or the umbilical cord), bone marrow and fat, the latter two representing 
the most common sources [28–34]. There is a confusing amount of so-called specific markers to define 
this stem cell type, which, in addition, varies to some extent depending on their tissue origin. Thus, 
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most researchers agree and rely in the meantime on the minimal criteria as defined by the International 
Society of Cellular Therapy. To do so, MSCs should adhere to plastic under standard culture 
conditions, they must be able to differentiate into osteoblasts, adipocytes and chondroblasts under 
standard in vitro differentiating conditions, as confirmed by specific stainings. Additionally, a positive 
expression pattern (>95% of the cells) of CD73, CD90, CD105 is required as well as the absent 
expression (>98% of the cells) of CD45, CD34, CD14 or CD11b, CD79 or CD19 and HLA-DR [35]. 
Recent publications showed that, next to the cell source, the MSC population itself seems to be a 
heterogeneous mix of pre-committed and differentially methylated cells. Purinergic receptors and 
PTHrP are marker to define and distinguish these cells within a population [36–38]. The amount of the 
intensively investigated bone marrow-derived MSCs is rather limited which led to a shift of interest in 
an alternative source where higher amounts can be obtained, harboring a higher yield of cells in recent 
years. Adipose tissue-derived stem cells (ATSCs) are therefore of major interest. Here, the MSCs can 
be collected from the waste product of liposuction surgery applied on healthy donors [39,40]. 
Undifferentiated MSCs and MSCs differentiated towards ECs and SMCs are used for experiments in 
vascular research. They are investigated as stabilizing supporter cells for vascular networks or directly 
in TEVG. Cell culture models as test systems for preliminary biocompatibility studies and in vivo 
models, both with and without differentiation studies, are the main approaches to investigate the 
potential of MSCs to form vascular structures.  
2.3.1. Endothelial Cell and Smooth Muscle Cell Markers Expressed in Differentiated MSCs 
The differentiation and angiogenic potential of hMSC is evaluated under two diametrically opposed 
aspects. Some researchers are interested in understanding angiogenesis to be able to inhibit tumor 
microvessels development as cancer treatment. Others are interested in understanding angiogenesis for 
future tissue replacement strategies in regenerative medicine. Understanding the underlying basic 
mechanism is the common ground for both. Thus, selected publications of the former are mentioned 
within this paragraph as well. One example for this is the work of Birnbaum and colleagues who 
differentiated hMSCs under the influence of glioblastoma-conditioned medium and confirmed the results 
of EC and SMC markers expression via tube-formation assays [41]. The tumor-conditioned hMSC 
expressed CD151, VE-cadherin, desmin, alpha-smooth muscle actin, nestin and nerval/glial antigen 2 
(NG2). Since no expression of von-Willebrand factor (vWF) and smooth myosin could be detected, these 
findings indicate a GBM-dependent differentiation of hMSC into pericyte-like cells, rather than into 
endothelial or smooth muscle cells. Kim detected EC and SMC markers (CD34, CD31, KDR, VEGF and  
alpha-smooth muscle actin) with immobilized bFGF using a decellularized natural matrix [42]. Duffy 
and colleagues used a collagen based matrix to establish a nascent vascular network in vitro within this 
glycosaminoglycan matrix [43]. To do so this group seeded the scaffold with MSCs and showed that the 
cells expressed PECAM-1 and VCAM but there was no increase in Tie-2 and vWF expression and the 
alpha-smooth muscle actin expression fell. 
2.3.2. MSCs for in Vitro Differentiation Assays 
The differentiation of MSCs can be influenced by mechanical and physical stimulation such as 
elasticity and geometry, shear stress and pressure, or pH and oxygen, and various soluble and bound 
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chemical factors from the matrix. For a review on this, see Schulze and Tobiasch [6]. Exemplary  
EC and SMC differentiation assays with the center of attention on mechanical and physical stimulation 
are listed in the following. Song and colleagues focused on mechanical properties such as flexibility  
and an elastic porous tubular structure of poly(1,3-trimethylene carbonate), PTMC, cross-linked by 
gamma-irradiation in an inert nitrogen atmosphere with an interconnected pore network prepared by 
particulate leaching for tissue engineering of small-diameter blood vessels which they tested for 
biocompatibility [44]. Tsigkou achieved anastomosis and human-derived vessels with long term stability 
where the majority of the graft vasculature had been functionally remodeled with host cells while 
generating vascularized bone grafts using mesenchymal stem cells from human bone marrow and 
umbilical cord-derived endothelial cells in the very stiff material derived from decellularized allogeneic 
bone grafts [45]. Gong on the other hand developed a two-step model to engineer small-diameter vessels 
by seeding BM-MSCs onto a very soft fibronectin and collagen matrix showing differentiation into  
SMC under the influence of soluble factors (TGF-β1, PDGF-bb) and cyclic strain. Histological and 
molecular examinations showed similarities to native vessels [46]. 
2.3.3. MSCs for Vascular Grafts in Animal Models 
For in vivo models investigating the potential of MSCs in vascular healing, TEVGs have been 
developed by using natural, natural-derived and artificial materials for scaffolds, with collagen and 
matrigel being the most common materials. A typical example for the former is the work of Kim  
and coworkers who successfully cultured hATSCs and various other cells on a decellularized  
human extracellular matrix from adipose tissue investigating the usefulness of such a natural scaffold 
material [47]. Zhao and colleagues developed a tissue-engineered artery using autologous bone 
marrow derived mesenchymal stem cells (MSCs) differentiated into (SMCs)-like cells and endothelial 
cell (ECs)-like cells, seeded onto decellularized ovine carotid arteries and interposed into the carotid 
arteries in an ovine host model [48]. The group of Dufourcq modified murine MSC genetically to secrete 
frizzled-related protein-1, a modulator of the Wnt/Fz pathway and showed that they recruited ECs and 
SMCs to enhance neovessels maturation in a mouse engraftment model [49]. Altman, using a  
natural-derived artificial scaffold, seeded hATSCs on a silk fibroin-chitosan (SFCS) scaffold in a 
murine soft tissue injury model and showed positive expression patterns of fibroblasts (hsp47), EC 
(vWF) and SMC (alpha-smooth muscle actin) [50]. Chung and his group observed network formation 
in a three-dimensional matrigel by tracing ATSCs from rats via nanoscaled gold spheres [51]. 
Matsumura and colleagues seeded tissue-engineered vascular autografts with bone marrow cell for 
future repair of complex cardiac defects and successfully tested the graft transplanted in the inferior vena 
cava of dogs for various early and late EC and SMC marker [52]. Cho and Lim used a hybrid 
biodegradable polymer scaffold from poly(lactide-co-epsilon-caprolactone) (PLCL) copolymer reinforced 
with poly(glycolic acid) (PGA) fibers to produce a tissue-engineered vascular patch by using 
autologous bone marrow-derived cells in the dogs [53,54]. While Mendelson and colleagues  
developed a two-step model using ovine blood-derived endothelial progenitor cells (EPCs) and bone 
marrow-derived MSCs seeded onto poly-4-hydroxybutyrate (P4HB)-coated polyglycolic acid (PGA) 
nonwoven biodegradable mesh scaffolds first applied to flow in a bioreactor and later in vivo, using 
cell-seeded patches implanted in the sheep pulmonary artery [55]. A very different question was 
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addressed by Derval and coworkers who used murine MSCs and EPCs on coated muscle patches as 
therapy approach for distance of myocardium infarction (MI) in a mouse model. They showed that 
only MSCs exhibited the capacity to invade scar tissue [56]. 
2.4. Endothelial and Smooth Muscle Progenitor Cells 
The plasticity of stem cells always encloses the risk of tumor formation which to some extent is linear 
to the potency of the cells. In addition this flexibility to differentiate in several lineages also contains the 
risk of undesired spontaneous differentiations towards the wrong tissue type. On the other hand, the use 
of fully differentiated tissue cells is limited due to the low cell amount achievable and problem with 
long-term culture. This makes precursor cells which still have some although limited differentiation 
potential combined with a reasonable good proliferation capacity an interesting cell type. 
When the group of Ashara and later Shi discovered the existence of endothelial progenitor cells 
(EPCs) derived from bone marrow (BM-EPC), a new cell type was available which seemed to be  
an ideal cell source for vascular healing approaches providing an appropriate amount of ECs and 
SMCs [57,58]. EPCs can also be obtained from peripheral blood (PB-EPC), umbilical cord (UC-EPC), 
and umbilical cord blood (UB-EPC). They can be differentiated into ECs in the presence of growth 
factors such as VEGF, basic fibroblast growth factor (bFGF), and insulin-like growth factor-1  
(IGF-1) [59,60]. Interestingly, EPCs circulating in peripheral blood (PB-EPC) settle on denuded 
endothelial sites within the vessels. Shirota and coworker mimicked this natural behavior of the  
cells [61]. They isolated EPCs from human blood and performed in vitro studies with the cells and a 
microporous segmented polyurethane film coated with a photo-reactive gelatin layer and applied to 
flow shear stress. They observed EPCs fully covering the graft elongating and aligning themselves 
with the direction of the flow similar to native EC. 
2.4.1. EC and SMC Expressed in Differentiation Assays of Vascular Precursor Cells 
The definition of specific marker in vascular precursor cells is interesting because they are a defined 
natural stage between the non- or little committed stem cells and the fully differentiated tissue cells. 
Since the appearance and disappearance of so-called stage specific markers is always difficult due to 
the process being a fluent event and not a sudden onset after the initiation of differentiation towards 
the desired lineage, a defined set of minimal criteria as for MSC would be desirable but has not been 
agreed upon until now. 
Le Ricousse-Roussanne and Amini isolated progenitor cells and detected EC and SMC markers, 
while Davis injected peptides that recruited progenitor cells expressing EC and SMC  
markers [62–64]. The group of Le Ricousse-Roussanne obtained cells from cord blood and 
investigated if these progenitor cells are a source for vascular therapy. They could show that 
cobblestone-like cells expressed endothelial cell markers, while spindle-shaped cells expressed SMC 
markers. Amini compared EPC from rabbit peripheral blood (PB-EPC) and bone marrow EPC  
(BM-EPC). PB-EPC displayed EC markers like CD31 and a high angiogenic potential in a 3D matrix. 
Co-cultured with MSCs, the cells expressed high levels of osteogenic and vascular markers  
(AP, bone morphogenic protein 2, VEGF). BM-EPC did not express PECAM-1, but it did express 
smooth muscle markers [63]. Davis injected self-assembling peptides in the myocardium and detected 
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recruitment of progenitor cells expressing EC and SMC markers in the microenvironment of the 
nanofibers produced by the peptides [64]. 
Differentiation studies were conducted by Sainz, Sreerekha and Wu [65–67]. They also showed 
expression of specific EC- (PECAM-1, VE-cadherin, vWF) and SMC (aSMA, calponin, SMA, HC) 
markers in the resulting cells. Allen and co-workers engineered a functional endothelium on a polymer 
by using EPCs from porcine peripheral blood [68]. The EPCs differentiated into ECs and expressed  
EC markers (vWF, PECAM-1, VE-cadherin) as well as ac-LDL uptake. In a co-culture model, the 
influence on porcine aortic smooth muscle cells (PASMC) was investigated and showed a decrease in 
PASMC proliferation. Cherqui used ECs and EPCs and transduced them using viral macrophage 
inflammatory protein-II (vMIP-II), which is immunosuppressive and proangiogenic [69]. They 
engineered vMIP-II lentiviral gene vectors and transplanted matrigel templates and observed 
functional and branching vessels with associated smooth muscles. Schmeckpeper cultured  
BM-EPC-derived ECs on collagen and BM-derived SMC on fibronectin in order to investigate vector 
ability to track vascular differentiation, showing EC markers VE-cadherin and expression of eNOS and 
SMC markers aSMA, calponin and SM myosin HC [70]. Fioretta and colleagues investigated the 
influence of substrate stiffness on progenitor cells fate [71]. They seeded EPCs from peripheral blood 
on soft, intermediate, and stiff fibronectin-coated polyacrylamide gels and analyzed adhesion  
(vinculin staining), proliferation (BrdU), phenotype (CD31, aSMA, FACS analysis), and collagen 
production. They observed that adhesion and proliferation increased with substrate stiffness but no 
influence on change of phenotype could be seen. Clever and colleagues did an inhibition study using 
EPCs and hCASMCs [72]. They showed that application of paclitaxel, sirolimus and iopromide 
inhibited proliferation and migration in a dose-dependent manner. 
2.4.2. Endothelial and Smooth Muscle Progenitor Cells for Vascular Grafts in Animal Models 
Basic studies and the potential of vascular progenitor cells to promote vascular healing has  
been investigated in small and large animal models with EPCs being the major focus of attention, but 
co-recruitment of EPCs and SMCs progenitor cells has been examined, too. Fioretta and colleagues 
investigated the fate of EPCs on scaffolds with different degrees of stiffness [71]. Cottone registered a 
patent using a drug delivery graft recruiting EPCs for restoring an endothelium [73]. Melero-Martin 
co-cultured EPCs from various sources (human umbilical cord blood, peripheral blood, and human 
saphenous vein smooth muscle cells (HSVSMCs)) on matrigel and implanted the grafts into mice to 
form vascular networks [74]. Griese and colleagues isolated EPCs from blood to re-endothelialize 
balloon-injured carotid arteries in rabbits with and without bioprosthetic grafts [75]. They observed 
inhibition of neointima deposition. Similarly, he and colleagues transplanted autologous circulating 
endothelial progenitor cells prelined on the luminal surface of in situ-formed collagen type I meshes as 
extracellular matrix wrapped with a segmented polyurethane thin film in canine arteries [76]. The graft 
should serve as small-diameter-vessel prostheses and ensure nonthrombogenicity. Allen used EPCs  
from circulating blood to engineer a functional endothelium on poly(1,8-octanediol-co-citrate), a 
hemocompatible and biodegradable elastomer for vascular tissue engineering in a pig model [68].  
Yu and coworker showed the simultaneous recruiting of ECs and SMCs progenitor cells for in situ 
blood vessel regeneration in rats [77]. 
J. Clin. Med. 2014, 3 51 
 
 
2.5. Patents on Adult Stem and Precursor Cell Isolation and Maintenance 
This paragraph summarizes in brief patents on isolation, characterization, proliferation, migration 
and differentiation of adult stem and precursor cells. Some multipotent stem cells next to MSC are 
discussed because the application of various precursor and adult stem cells, mainly MSCs increased in 
patents during the last ten years (Figure 1C). Some differentiations of applications diverse form the 
area of this review will be mentioned briefly because they provide insides into the more general 
aspects of the above-mentioned features and thus will be beneficial for researcher interested in the 
topic of this review. Scaffolds will be introduced here only in a few words because they are discussed 
thoroughly in the second part of this review. 
The patented isolation procedures can be divided into those which describe specific mechanical 
techniques and those which rely on chemical procedures to improve the outcome. Noishiki patented a 
mechanical method to harvest stem cells of bone marrow from long tubular bones [78]. Muschler 
suggested another method to do the same [79]. Sciorra’s invention relates to a culture system suitable for 
high throughput screening applications using a 3-dimensional tissue models that may be used to identify 
new drugs [80]. Harman’s invention is to prepare a stem cell composition from a collagen-based tissue, 
such as adipose tissue, isolated from a patient and subsequently provide it to a site of injury [81]. 
Kieda described a method to isolated human precursors of endothelial cells to create cell lines for 
future application [82]. Ma suggested seeding MSC on a planar surface or a porous 3-D scaffold 
comprised of non-degradable polymer such as poly(ethylene terephthalate) (PET) and grow the cells 
under physiological or low O2 tension to maintain their self renewal capacity [83]. Xianqun has 
patented a hermetic material, which is a soft silica gel or a sticky plastic film [84]. The material is 
supposed to be put under negative pressure so that the stem cell suspension completely reaches the 
inside of the porous biomaterial for fusion. To isolate or improve the proliferation of adult stem cells, 
several inventors followed strategies using peptides and cytokines. Gostjeva’s invention provides 
methods identifying molecules to modulate proliferation and/or migration of metakaryotic stem cells 
disorders, such as blood vessel wound healing disorders, including restenosis [85]. Amoh claimed 
nestin expression as a marker for endothelial cell proliferation [86]. Lee’s invention provides a method  
for inducing in vivo migration of stem cell using a biodegradable scaffold with various chemotactic 
factors [87]. Hantash has differentiated MSCs towards fibroblasts with various cytokines on various 
scaffolds, namely hydrogel, PLGA, collagen gel, matrigel, spongastan, and fibronectin [88]. Guoqi has 
patented the use of facial masticatory muscles genetically altered towards cardiac muscles cells, which 
have the same origin for the progenitor cells, on a cell membrane technique [89]. Nanxue’s invention 
relates to a method used to process directional-inducing ATSC towards adipose and endothelial cell 
differentiation and the combination of the cells with a biomaterial to remedy soft tissue defects [90]. 
Shortkroff has patented a double-structured tissue implant composed of a soluble collagen in 
combination with a non-ionic surfactant positioned within the primary scaffold for differentiation  
and growth of mesenchymal and bone marrow stem cells [91]. Park attempted to achieve growth and 
differentiation of stem cells by modifying the surface of the polymeric scaffold using the 
decellularized extracellular matrix directly derived from specific tissue cells [92]. Aicher suggested the 
same for mesenchymal progenitor cells of the umbilical cord [93]. Hamada introduced a carbonate 
apatite-collagen sponge comprising the SVVYGLR peptide which can stimulate the proliferation  
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of mesenchymal and dental pulp cells. This is supposed to be useful a biomaterial for the regeneration 
of bone marrow or dental pulp [94]. Cho found that scaffolds with a high content of sulfated 
glycosaminoglycans facilitate cell adhesion and provide biomimetic surface environments that are 
effective for growing and differentiating stem cells [95]. Komeno used anaplastic mesenchymal  
stem cells embedded in a gel forming material such as collagen and hyaluronic acid [96]. Similar, 
Huang claimed that stem cells display improved viability when grown in a cell tissue gel that contains 
collagen and hyaluronan at particular weight ratios [97]. A modification of this is the patent of 
Abatangelo who suggested using differentiated bone marrow stem cells seeded on an extracellular 
matrix and a second component biodegradable matrix consisting of a hyaluronic acid ester [98]. Choi 
described a medical composite biomaterial comprising collagen and a hyaluronic acid derivative  
using stem cells derived from a mammal umbilical cord [99]. This is very similar to the suggestion of 
Komeno who patented anaplastic mesenchymal stem cells embedded in a gel forming material such as 
collagen and hyaluronic acid [96]. A two component scaffold was also favored by Min who patented 
the use of an alginate coated fibrin/ha composite scaffold [100]. Another two component scaffold was 
patented by Shimizu [101]. He wants to use an artificial blood vessel comprising a tube made of a 
supporting skeletal material and a collagen layer of ultrafine fibers at the outside of the tube. Some 
patent holders suggest not using the stem cells itself but rather a secreted product thereof. The strategy 
of using conditioned medium of MSCs for multiorgan failure was tracked by Westenfelder [102]. Arai 
suggested a new method for producing type 14, 12 collagen for wound healing from genetically altered 
stem cells [103]. 
3. Primary Tissue Cells for Vascular Grafts 
Some researchers prefer primary vascular cells instead of precursor or stem cells. This might be due 
to the fact that these cells do not feature the tumourigenic potential typical for cells with a higher 
plasticity. On the other hand this advantage is abolished by the restricted access to the cell sources in 
humans, namely umbilical cords, aorta, coronary arteries and veins, and the fact that the differentiated 
primary cells also lack the self renewal capacity of the stem cells. Thus the use of these cell types in 
constant but rather low over the last decade (Figure 1B,C). 
3.1. Endothelial Cells 
Endothelial cells constitute the inner wall of blood vessels by forming a monolayer. They form  
a barrier for erythrocytes but provide the transition of hormones, oxygen, nutritional factors, and  
other proteins and take part in the regulation of blood pressure through the enzyme endothelial  
nitric monoxide synthase (eNOS) and the resulting production of nitric monoxide (NO) causing 
vasodilatation of the vessels. Heme oxygenase 1 is another important enzyme producing carbon 
monoxide and modulating EC apoptosis [104–106]. An additional feature is the production of clotting 
factors to influence the viscosity of the blood. Further ECs take part in immune response by their 
ability to bind leukocytes and activate them. The monolayer formed by ECs is often described as 
“cobblestone pattern” due to their polygonal shape. ECs express specific proteins, which are used to 
identify them via histological and immunohistochemical stainings as well as expression patterns on the 
RNA and protein level, including platelet derived adhesion molecule-1 (PECAM-1/CD31), von 
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Willebrand factor (vWF), vascular endothelial cadherin (VE-cadherin), and the VEGF-receptor-2 
(kinase-insert domain receptor (KDR)/fetal liver kinase-1 (Flk-1)). Sources of ECs are capillaries, 
arteries, aortic vessels and veins of a multiplicity of organisms. They can be isolated via digestion of 
tissue or by scraping the monolayer of vessel. Jaffe and colleagues described a procedure to isolate and 
expand ECs from human umbilical cords (therefore named human umbilical cord endothelial cells, 
HUVEC), whereas Voyta isolated primary ECs from bovine capillaries and aortic vessels via cell  
sorting [107,108]. Knighton patented a method using sponges in wounds to isolate microvascular ECs. 
The cells surrounding the wound and can invade the sponge, which can be degraded subsequently [109]. 
3.2. Smooth Muscle Cells 
Smooth muscle cells of the vasculature are located in the media of arteries and veins. The principal 
task of SMC in arteries is to regulate the blood pressure by vasodilatation and vasoconstriction and to 
provide mechanical strength of the vessels [110]. SMCs are spindle-shaped and also express specific 
proteins like alpha-smooth muscle actin (αSMA), smooth muscle myosin heavy chains, and calponin. 
Those proteins can also be used to identify SMCs via histological and imunnohistochemical staining  
as well as expression patterns on the RNA and protein level. The maintenance of homogeneous SMC 
populations is more extensive than EC populations. Due to their location in the media of vessels 
surrounded by elastic fibers like elastin, digestion of the tissue or the outgrowth of vessel rings and 
tissue pieces must be performed. The challenge is to maintain vessels without an inner monolayer  
of ECs, which can be done by digestion, e.g., collagenase, conducted by Jaffe for isolation of  
HUVECs [107]. Additionally, the adventitia has to be removed to ensure an outgrowth of the SMCs, 
which can last a long time. Another threat to homogeneous populations of SMCs is the cross-border 
population with fibroblasts, which are similar in morphological shape. SMC isolation has been 
conducted from various animal models and different human tissues (e.g., human coronary artery, 
human umbilical artery/vein). Ray and co-workers isolated SMCs from murine aorta, whereas Ribeiro 
isolated SMCs from human umbilical cords [111,112]. 
3.3. Endothelial Cells and Smooth Muscle Cells for Vascular Grafts 
ECs strictly grow as monolayers in vivo and therefore it is required to transport the cells from a 
two-dimensional culturing system into a three-dimensional environment like a graft. Several studies 
have been concerned with the investigation of co-culture models on a three-dimensional matrix and the 
influence of the matrix. This research is often connected to animal models in order to observe the 
potential of vascular healing. Co-culture of ECs and SMCs on grafts mimic in vivo conditions and 
enhance vascular properties. Fillinger and colleagues co-cultured ECs and SMCs on opposite site of a 
porous membrane and observed the formation of gap junctions between each other [113]. The effect of 
direct contact was investigated by Wallace and colleagues, co-culturing ECs and SMCs in comparison 
to a co-culture on porous membranes [114]. Direct contact led to low levels of intercellular cell 
adhesion molecule-1, vascular cell adhesion molecule-1 and E-selectin surface protein, all necessary 
for monocyte transition through EC layer during atherosclerotic inflammation. Their conclusion is that 
direct contact of ECs and SMCs in co-cultures on grafts render graft ECs more resistant to 
inflammatory signals. Chen and colleagues investigated the effect of copolymers on the proliferation 
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of ECs and SMCs [115]. They showed that vascular cells grew well on moderately hydrophilic 
membranes. The working group of Kim BS seeded HUVEC on decellularized human  
adipose-tissue-derived extracellular matrix sheets and observed spreading of the cells and integration 
into the matrix [47]. Baguneid went one step further and developed a tissue-engineered blood vessel on 
a collagen scaffold [116]. ECs and SMCs were seeded on a collagen matrix and transplanted into pigs. 
The TEBV showed endothelialization and neo-vascularization. Boni replaced left pulmonary arteries 
of lambs with porcine small intestine sub-mucosal biomaterial and confirmed the presence of SMCs in 
the medial layer [117]. Callegari implanted porous collagen scaffolds on cryo-injured rat hearts [118]. 
The collagen scaffolds were absorbed and became populated by new arterioles and capillaries. The 
cells expressed EC and SMC markers and no cardiomyocyte markers. Similarly, Saif developed 
biodegradable PGA scaffolds that released VEGF, HGF, and angiopoietin-1 as combination or  
sole [119]. In a murine hindlimb ischemia model they found out that increasing migration of vascular 
progenitor cells took place when all factors were secreted. The scaffold was vascularized with an 
increasing capillary density. Also the number of SMCs increased, indicating the stabilizing role of 
these cells. Denuded ECs no longer inhibit SMC from migrating into the vessel lumen and as a 
consequence the SMCs narrow the blood vessels. Stoeckius and colleagues investigated the essential 
pathways in growth arrest of SMCs [120]. The observations provide important mechanistic insight into 
the molecular mechanisms underlying the transition of human vascular smooth muscle cells from 
proliferative to contractile phenotype and the role of bilirubin in this transition. 
Patents on Endothelial Cells and Smooth Muscle Cells for Vascular Grafts 
Patents using and affecting ECs or SMCs have been published nearly every year. The majority  
of patents aim the inhibition of SMC proliferation and migration. Therefore the injection of  
different pharmaceutical agents like peptides is one way to treat vascular diseases. Nabel patented  
a polynucleotide comprised of a thymidine-kinase gene, inhibiting SMC proliferation, whereas  
Suda developed an antibody against calcification of atherosclerotic plaques [121,122]. Wolinsky 
developed a catheter harboring balloons filled with heparin to prevent restenosis by inhibiting SMC to 
proliferate [123]. Altman patented a method for delivering therapeutic amounts of anti-restenotic  
agents [124]. Edelman and Uchida built matrices, which can be seeded with ECs or SMCs [125,126]. 
An adequate amount of ECs on the scaffold inhibits SMC proliferation. Takano developed an artificial 
vessel by coating collagen and fibronectin with SMCs, whereas Cao developed an apparatus to 
construct blood vessels in vitro [127,128]. Within this device ECS and SMCs are exposed to 
biomechanical factors to stimulate proliferation, directional arranging, and the production of 
extracellular matrix proteins. Other inventions aim the induction of endothelialization, e.g., by 
secreting agents to target EC migration. Burleigh patented a polypeptide to recruit ECs and the group 
of Jianhong, registered a scaffold containing amino acid sequences of collagen to capture  
ECs [129,130]. The scaffold maybe used as tissue engineering blood vessel rack, on which smooth 
muscle cell and/or endothelial cell may be planted. Iwazawa’s invention comprises a recombinant 
gelatin with an amino acid sequence derived from collagen [131]. Hoganson patented an in vitro model 
with a seeded (ECs and SMCs) scaffold to investigate the influence of pharmaceutical agents [132]. 
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3.4. Other Primary Tissue Cells for Vascular Grafts 
Although ECs and SMCs are the most prominent cells of the vasculature, other primary tissue cells 
have been investigated in view of their potential to promote vascular healing as well. Interesting 
candidates are cardiac precursor cells such as myoblasts, myofibroblasts, fibroblasts, and metakaryotic 
stem cells. While the obvious use of cardiomyocytes is more or less limited to the heart, fibroblasts are 
part of the blood vessel structure. Fibroblasts are of mesenchymal origin and present the main cells of 
connective tissue, synthesizing collagen and the extracellular matrix and thus the structure of the 
tissues. This makes them a suitable link in grafts between a biomaterial and the seeded tissue-specific 
cells. Kim and colleagues seeded among others dermal fibroblasts on decellularized human  
adipose-tissue-derived extracellular matrix sheets and observed their integration into the matrix [48]. 
Their results suggest that recellularized ECM sheets are a promising substitute for defective human 
tissues, including blood vessels. Kellar stimulated angiogenesis within a region of cardiac infarction  
used a scaffold-based 3D human dermal fibroblast culture as epicardial patch [133]. They observed 
higher numbers of arterioles, venules and capillaries in comparison to control groups and conclude the 
potential use for myocardial tissue repair. Tosun and his colleague seeded human myofibroblasts onto 
the abluminal site of ex vivo derived vascular collagen/hydrogel scaffolds and investigated different 
culture conditions [134]. The cells migrated towards the source of nutrients displayed by the perfused 
lumen of the decellularized vessel. Formigli and colleagues transplanted myoblasts into a chronic MI 
region of pigs and observed settlement of these cells in the ischemic scar and around blood vessels 
with an activated endothelium [135]. The invention of Gostjeva provides methods to identify 
molecules to modulate proliferation and/or migration of metakaryotic stem cell disorders, such as 
blood vessel wound healing disorders, including restenosis [85]. 
4. Summary of Cell Types for Vascular Grafts 
The nearly unlimited supply of ESCs due to their self renewal capacity, in combination with their 
ability to differentiate into any cell type of the germ layer, makes this cell type a very interesting 
candidate for future approaches in regenerative medicine. However, their ability to expand indefinitely 
in vitro in cell culture gives also rise to spontaneous teratoma formation in vivo, displaying a  
non-negligible potential risk for patients. In addition, the use of ESC is limited in many countries due 
to ethical concerns related to the isolation of these cells from early embryos [2]. A promising other 
pluripotent stem cell source, iPS, was introduced in 2006 by Takahashi and Yamanaka [4,5]. This 
artificial cell type can be produced in large amount from various tissues which not only limits the 
ethical concerns, but also provides the possible use of autologous cells. Thus, it is not astonishing that 
applications of ESC in vascular healing approaches are decreasing, while approaches with iPS as cell 
type of choice are rising. Unfortunately, iPS have a similar risk to cause teratoma formation as ESCs, 
which is not dwindling substantially, because the reprogramming process is no longer done using 
retrovirus-derived vectors which have a carcinogenic potential on their own. The risk of causing 
teratoma is linked to the pluripotency of the cells and the fact that until now there is no protocol 
leading to ESC or iPS differentiation in 100% of the induced cells. Hence, adult stem cells with their 
lower plasticity are the focus of attention in most publications and patents linked with vascular healing 
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(Figure 1). The most commonly used adult stem cells are mesenchymal stem cells obtained from bone 
marrow and adipose tissue. These cells can be differentiated into the desired cell types, namely 
endothelial and smooth muscle cells and expanded in cell culture to reasonable amounts for future 
applications in patients. Most researchers agree that immune reactions to this cell type are low and, 
anyway, they can be isolated from the patient itself if adipose tissue is the cell source. However, 
possible tumor formation, although less than in pluripotent stem cells, cannot be neglected. A new cell 
type with a lower potential caught the attention of scientists when it was discovered that most tissue 
contain precursor cells which were thought to be present only in tissue types with a high cell turn-over 
or a high regeneration potential. With the discovery of EPCs by Ashara and Shi, a new cell type for 
vascular research was at disposal that could be isolated from peripheral blood of a patient, thus causing 
no undesired immune reactions, and easily be differentiate into ECs and SMCs [57,58]. At the same 
time period, other stem and precursor cell types with variable plasticity were indentified and explored 
as well (see Section 3.4). Primary tissue-derived ECs and SMCs have been an early choice due to their 
natural role in the vasculature. But the limited availability of this cell type in humans due to the cell 
source being arteries and veins, the high risk of immune reason using allogenic approaches (if the cells 
are not derived from the umbilical cord), besides the very limited possibility for long-term culture and 
proliferation in vitro keeps the interest in this cell type to a steady but low level. 
Taken together, the number of publications and patents using a huge variety of stem and precursor 
cells with distinct but divers plasticity for grafts promoting vascular healing is increasing. Figure 2 
gives an overview of cell sources used to promote vascular healing. The success of such an approach is 
also dependant on the scaffold material which must be adapted not only to the respective tissue but 
also to the used cell type. Only a well-founded understanding of the metabolism of the respective cell 
type, combined with a tightly monitored and orchestrated procedure using the chosen well-tailored 
biomaterial might lead to a successful application of these grafts in human in the future. 
5. Scaffolds for Stem Cell Engineering 
The targeted control of the microenvironment for stem cell engineering plays a key role in tissue 
engineering of vascular grafts. The mimicking of the natural microenvironment by scaffold materials 
includes both biochemical and biophysical aspects. Whereas biochemical interactions of scaffold 
material and cells are dominated by the specific chemical structure of the scaffold surface, the 
biophysical requirements like matrix rigidity and matrix actuation can vary by several parameters,  
e.g., scaffold porosity and degradability. A broad spectrum of required properties was identified. The 
materials’ properties portfolio should support cell adherence, survival and proliferation, include 
biocompatibility, and—with respect to the desired function—higher or lower rates of biodegradability. 
Additionally, the mechanical and physical properties should match the same range as native tissues. 
Therefore, artificial three dimensional tubular scaffolds must exhibit a highly porous structure to allow 
cell adherence and proliferation. For vascular grafts, completely biological materials like cells on 
endothelial cell matrix (ECM) or bioartificial materials mostly consisting of synthetic polymeric 
scaffolds covered with cells are addressed in various studies and recently reviewed by Parizek and 
Chlupac [136,137]. 
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Figure 2. Cells used on grafts to promote vascular healing. The picture shows the different 
sources of cells used to promote vascular healing. Endothelial cells and smooth muscle 
cells can be obtained directly from primary tissue, e.g., arteries or umbilical cord or via 
differentiation of stem cells. Those stem cells can also be used directly on a graft. The cells 
can differentiate into the desired cell type and then be transplanted into animal models. 
 
Engler, Gilbert and Holst demonstrated the crucial role of mechanical properties, especially the 
elastic behavior and scaffold stiffness, though showing that the stiffness contributes significantly to the 
mesenchymal stem cell differentiation and the self-renewal [138–140]. 
5.1. Scaffolds Materials 
The development of tailor-made scaffolds for vascular healing shows promising results, and as a 
result, a tremendous number of papers and patents delve into the identification of suitable materials. In 
general, scaffold materials for stem cell engineering can be based on natural and synthetic polymers. 
Both groups can be subdivided into degradable and non-degradable materials (see Figure 3). Synthetic 
and natural materials are addressed as well as combined approaches. In the following, an overview will 
be given of the current state-of-the-art scaffold materials, including fabrication techniques and criteria 
for scaffold evaluation. 
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Figure 3. Scaffolds materials for stem cell engineering of vascular grafts. This scheme 
gives an overview about the materials discussed in this review with respect to the origin of 
the scaffold material. Synthetic and natural materials are addressed in the discussion as 
well as combined approaches to scaffold materials. 
 
5.1.1. Synthetic Polymers 
The use of synthetic polymers allows a target-oriented design of desirable properties. The chemical 
structure, molecular mass, and its distribution can be controlled by the synthesis method of the 
polymer material. 
(a) Non-degradable polymers 
Non-degradable materials are mostly chosen to provide a scaffold with long-term stability. 
Materials like polyethylene terephtalate (PET), commercially produced as Dacron®, and 
polytetrafluoroethylene (PTFE), also known as Gore-Tex®, are candidates that dominated the first 
developments of artificial vascular grafts. The mechanical properties are incompatible with soft tissue 
regeneration, but are advantageous in composite scaffolds. A recently published study demonstrates 
the utilization of polyesters as carrier material for collagen. In vivo experiments were performed by 
Baguneid and colleagues to develop tissue-engineered small-diameter vascular bypass grafts [116]. 
Within the last two decades, other polymers have been studied including poly(ethylene glycol)s, 
polycarbonates, and polyurethanes. Poly(ethylene glycol) (PEG) is a hydrogel forming synthetic 
polymer. A large series of studies on vascular graft scaffolds focus on PEG and corresponding 
copolymers due to their ability to resist protein adsorption during in vivo application. Avoiding platelet 
adsorption is of high importance for the development of vascular implants. Benoit and colleagues 
studied the influence of small functional groups on controlled differentiation of hydrogel-encapsulated 
human mesenchymal stem cells [141]. PEG-based materials can be modified to adopt required 
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biofunctionalities, for example with proteolytic degradable peptides, adhesion peptides, growth factors or 
collagenase sensitive peptide sequences [142]. Acrylated PEGs can be photopolymerized in direct contact 
with cells and tissues [143]. Polyurethanes can be synthesized using a broad variety of appropriate 
monomers. Based on the chemical structure of the monomers, polymers with adjustable properties and 
high biocompatibility can be prepared for medical applications. In terms of in vivo or in cell culture 
conditions, polyurethanes are mostly non-degradable polymers. However, using some polyesterols as 
building blocks for polyurethanes can introduce a certain degree of degradability. Hemocompatibility 
and biocompatibility can be combined with designable mechanical properties ranging from elastomer 
properties to stiff and rigid polyurethane plastics [144,145]. Within the last two decades, polyurethane 
materials have been investigated as scaffold materials for various medical applications as described in 
many review articles [136,142,146,147]. Owing to its three-dimensional polymer structure, 
polyurethanes can take on many different forms including foams, microspheres, microcapsules, 
nanocomposites, and membranes [148]. Additionally, polyurethanes can be combined with natural 
materials to generate composites (see paragraph (c) Composites). Another porous non-degradable 
polymer used for tissue engineering of small-diameter blood vessels is poly(1,3-trimethylene 
carbonate) (PTMC). In particular, PTCM with a molecular weight of Mn = 4 × 105 g·mol−1 was  
cross-linked by gamma irradiation in an inert nitrogen atmosphere. The products are flexible elastic 
and creep resistant networks with 50%–70% gel content. Furthermore, PTMC is highly biocompatible, 
as determined by cell adhesion and proliferation studies using various relevant cell types [44]. 
(b) Degradable polymers 
Biodegradability has already been successfully implemented in certain artificial systems and 
presents a major advantage for tissue engineering of replacement vessels. However, certain 
biodegradable polymers are still not fully reviewed in terms of long-term toxicology. Degradable 
materials provide the opportunity to adjust the required scaffold properties during treatment and allow 
for a subsequent replacement of the synthetic material by naturally produced tissue. A broad variety of 
polymers have been studied in detail, including polyglycolic acid (PGA), polylactic acid (PLA), and 
copolymers there of like PGA-PLA, polycaprolactone (PCL) and copolymers with polylactic acid 
(PLA-PCL), poly(1,8-octanediol-co-citric acid) (POC), corresponding citric acid-based biodegradable 
elastomers, and glycosaminoglycans (GAG). 
For the evaluation of the use of an induced pluripotent stem cell sheet for the construction of  
tissue-engineered vascular grafts, PLA-based biodegradable tubular scaffolds were engrafted in 
congenital heart surgery. The transplantation of tissue engineered vascular graft was successful, safe, 
and effective in humans [26]. Co-polymers of polylactic acid and ε-caprolactone (PLA-PCL)  
are interesting biodegradable materials for vascular graft biodegradable tubular scaffolds. Bone 
marrow-derived mononuclear cells, differentiated smooth muscle cells, or endothelial cells were 
seeded onto PLA-PCL scaffolds. The results showed diverse cells living in the vascular drain 
exhibiting similar properties of native vessels [26]. Copolymers of polylactic acid, as well as 
polycaprolactone modified with polyglycolic acid, exhibited tensile mechanical properties more 
similar to those of dog inferior vena cava [54]. No sign of thrombosis, stenosis, or dilatation occurred 
up to eight weeks after implantation of vascular graft tissue-engineered polyglycolic acid modified 
PLA-PCL scaffolds cultivated with bone marrow derived mononuclear cells [53]. POC and citric  
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acid-based biodegradable elastomers were used as hemocompatible and biodegradable elastomers for 
vascular tissue engineering. Once differentiated, endothelial cells’ phenotype and function on POC 
were assessed according to presence of the EC-specific markers von Willebrand factor, platelet  
EC adhesion molecule, and vascular endothelia cadherin, metabolism of acetylated low-density 
lipoprotein, secretion of the anti-thrombogenic factors nitric oxide and prostacyclin, inhibition of 
platelet adhesion and clotting processes in vitro. Porcine endothelial-like cells on POC showed 
phenotype, function, and clotting responses similar to those of primary aortic ECs [68]. 
(c) Composites: Biobased materials on synthetic scaffolds 
The combination of synthetic and natural materials to form so-called hybrid scaffolds allows 
generating a wide range of parameters, adjustablein a manner that supports stem cell adhesion, 
differentiation and proliferation within a designed microenvironment [149]. Whereas the synthetic 
fraction of the scaffolds allows tailoring the physical and chemical properties of the material like 
mechanical behavior, wetability, and electrical properties, the control of cell behavior and biological 
activity can be achieved and varied by the bioactive components. 
Polyurethane/Collagen: The combination of collagen and polyurethane is very promising for cell 
culture scaffolds. The enormous potential of such hybrid scaffolds is evident in the following 
examples: A cell mixture containing Flk1-positive cells (ca. 30%) derived from murine embryonic 
stem cells was added to a compliant microporous tube made of segmented polyurethane. The luminal 
surface of the tube was fully covered with the cells by pre-incubation for two days in the presence of 
vascular endothelial growth factor. After two days of additional incubation without VEGF under static 
conditions, layering of the grown cells, mostly smooth muscle actin-positive cells, was observed only 
on the luminal surface of the tube [9]. Endothelial progenitor cells derived from the peripheral veins of 
dogs were isolated by using a density gradient method. The cells were proliferated in vitro in  
EGM-2 culture medium, pre-lined on the luminal surface of in situ formed collagen type I meshes  
as an extracellular matrix, and wrapped with a segmented polyurethane thin film with multiple 
micropores as a compliant scaffold [77]. 
PET/Collagen: Another opportunity is a combination of collagen with a synthetic scaffold  
material like poly(ethylene terephtalate), known as Dacron®, or expanded polyethylene terephtalate 
(ePET), which are still widely used since their first introduction in 1957 [150]. These scaffolds provide 
relatively good mechanical properties, but must be modified at the surface due to their hydrophobic 
character in order to allow the reconstruction of an endothelial cell layer. Especially in small diameter 
vascular grafts, the limited cell adhesion can cause thrombogenic effects due to adhesion of 
thrombocytes [142]. Van Damme and colleagues studied Dacron®-based scaffolds combined with 
collagen or other protein-based natural components like albumin or gelatin [151]. A loss of structural 
integrity of the graft resulted in limited longevity of both the implants as well as the scaffolds. The 
possibility of fiber reinforcement of a collagen matrix, e.g., using PET fibers, provides the opportunity 
to control and tailor the mechanical strength of the resulting hybrid scaffolds. Successful proliferation 
of MSC in PET reinforced collagen sponges is recently reported by Takamoto [152]. 
PEG/Glycosaminoglycans: Glycosaminoglycans are also used in combination with synthetic polymers, 
e.g., poly(ethylene glycol) for scaffold hybrid fabrication. Serving as a reservoir for growth factors,  
the glycosaminoglycan fraction in such hybrids allows a controlled delivery of the released factors. 
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Sustained delivery of SDF-1α from heparin-based hydrogels was studied by Prokoph and colleagues to 
attract circulating pro-angiogenic cells [153]. In detail, the influence of released SDF-1α on the 
surveillance of migration of endothelial progenitor cells was investigated. 
5.1.2. Natural Polymers 
Scaffolds based on natural polymers can be subdivided into (a) Decellularized scaffolds from 
different sources and (b) Artificial scaffolds from natural material components of the ECM. Many  
in vitro and in vivo studies are available that describe the use of biopolymers extracted from animal 
tissues. With respect to the imitation of extracellular microenvironments by the components of the 
ECM like collagen [118], elastin [154], and combinations thereof [155], a large variety of materials are 
studied regarding their influence on stem cell differentiation. Native tissues can be decellularized to 
obtain a scaffold material which reflects the structural characteristics of the natural microenvironment 
of the desired cells, as well as their chemical composition regarding the corresponding building blocks 
like collagen, elastin, or glycosaminoglucan [155]. Recently, a novel in vitro approach for anchoring 
ECM produced by cells to the surface of cultural carriers is described by Prewitz and colleagues [156]. 
This approach suggests that human bone marrow derived MSCs cultured on ECM modified carriers 
show proliferation rates three times higher than those under comparable cultural conditions. Since the 
microenvironment of such ECM-derived material mimics natural conditions, these experiments 
demonstrate impressively how to understand the control of stem cell differentiation and proliferation 
by biomolecular and physical signals of stem cell niches. 
Whereas the production of ECM under in vitro conditions requires complex and expensive 
techniques, collagen is available inexpensively in technical scale [157]. Collagen is widely used for 
artificial blood vessels and scaffolds prepared from fractions of the connecting tissue in tunica intima 
and tunica media [147]. The main advantages of collagen stem from the unique properties of this 
natural polymer, such as a low immunogenicity and good cell adherence properties, e.g., for 
endothelial cells [57]. There are two general options in using collagen: decellularized animal blood 
vessels and artificially designed scaffolds made from collagen hydrogels. Collagen hydrogels are  
well-suited as material for artificial scaffolds, since they are available in high qualities for medical 
applications. Successful collagen use as scaffold material for ex vivo differentiation of endothelial and 
smooth muscle cells from human cord blood progenitors in three-dimensional culture is reported by  
Le Ricousse-Roussanne [158]. Further interesting materials for cell culture include collagen sponges 
derived from freeze-drying processes, as described by Bohrer and colleagues [159]. Collagen sponge 
material is commercially available in several qualities for applications such as periodontal regeneration 
or wound healing [160,161]. 
Collagen is a suitable candidate to mimic important features of the stem cell niche environments, 
but does not provide enough mechanical strength required for vascular graft implants. As a result, 
many studies try to overcome this deficiency. One way to improve the biomechanical properties of 
collagen is the 3D network formation via crosslinking, applied either to a hydrogel or a structured 
collagen sponge-like matrix. Early studies from Chvapil and co-worker demonstrated that the  
sponge-like form allows cells to adhere and to proliferate within the pores of the sponge [162]. 
However, in many of the references about collagen-based scaffolds, no detailed information is given 
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about the origin and the pretreatment of the collagen, though this information is crucial for applications 
of collagen in stem cell engineering. 
Glycosaminoglycans are polydisperse mixtures of polysaccharide chains of varying lengths with  
an average molecular weight of 104–106 g/mol and a natural constituent of animal cells [163]. GAGs 
bind to proteins primarily through the interaction of its functional groups. Mainly the sulfo and 
carboxyl groups of the highly charged polyanions enable the interaction with a widespread variety  
of proteins [164,165]. The binding of heparin to antithrombin is well-known [166,167]. Specific 
oligosaccharide subsets within GAGs are the interacting parts with growth promoting proteins such as 
vascular endothelial growth factor (VEGF) [168]. 
Total synthetic approaches require simplification of the complicated GAG structure and ambitious 
multistep synthetic routes to control the structural setting and the stereochemistry [62,169–171]. 
Significant improvement of the synthetic approach was made by learning from nature about the role of 
enzymes in biosynthesis. The preparation of natural and artificial GAG analogues succeeded in 
applying three enzyme families: GAG lyases, synthases and sulfotransferases [172]. Today, 
glycosaminoglycans studies are driven by the evidence for a special ability to support the maintenance 
of vascular smooth muscle cells in quiescent and contractible manner [136,172]. 
5.2. Scaffold Fabrication Methods 
5.2.1. Conventional and Nano-based Fabrication Methods 
Conventional methods to generate polymer-based scaffolds include various moulding and casting 
processes, spinning, sintering, and extrusion techniques. The fabrication of three-dimensional scaffolds 
is possible by generating pores via particle or other selective leaching methods, phase separation and 
different gas forming methods. Polymer fibers can be treated via textile formation processes such as 
braiding, weaving, and knitting. Polymeric scaffolds have been investigated in form of foams, sponges, 
gels, or hydrogels. Additionally, scaffold surfaces are modified to deliver biologically active agents 
such as tissue growth factors such as VGEF, as reviewed in detail by Sachloz [173] and Moroni [174]. 
Gels and hydrogels are used for medical applications, particularly in drug-delivery. Within the  
last decade, hydrogels have also been studied as scaffold materials providing the possibility to 
encapsulate cells. Thus, a number of materials have been investigated including non-resorbable 
polymers, polyesters and polyamides, biodegradable polymers based on collagen, glycolic acid, lactic 
acid or hyaluronic acid. Natural biopolymers such as polysaccharides (e.g., hyaluronic acid  
derivative), synthetic polymers (e.g., poly(hydroxyethyl methacrylate)) or semi-synthetic derivatives 
(e.g., collagen-PLA composites) are able to form hydrogel structures. The corresponding three 
dimensional polymer networks can be realized via radical or photopolymerization, induced by 
ultraviolet irradiation or self-assembling peptide hydrogel structures supporting differentiation and 
transdifferentiation of cells. Stem or progenitor cells are encapsulated within these self-assembling 
peptide hydrogel structures. Thus, peptide-based hydrogels are developed and functionalized with 
growth factors or ECM components for controlled drug release, which enables the cells to differentiate 
or transdifferentiate within the structures [175]. The limited mechanical and viscoelastic properties of 
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hydrogels requires a combination with more stable 3D structures for scaffold application in tissue 
engineering [176]. 
Polymeric foams are widely used in medicine as scaffolds and drug release matrices. Polymer 
surfaces can be textured as a result of foaming processes. This is of vital interest since surface 
morphology and roughness have been demonstrated to influence the physiological response of cells 
such as cell attachment, morphology, and differentiation [177]. Porous foams based on racemic 
poly(lactide-co-glycolide) copolymers and microcellular foams made from biodegradable or  
non-biodegradable polymers with pores throughout the material having a diameter of about 1 to  
200 microns are investigated and approved for human clinical use [178]. 
Nanomaterials: The discovery of fullerenes (in 1985) and carbon nanotubes (in 1991) led to a 
tremendous development of novel nanomaterials. Additionally, investigations ensued regarding their 
use in medical applications [179–181]. Carbon nanotubes possess exceptional mechanical, thermal, 
and electrical properties, which facilitates their use as reinforcements or additives in various 
biomaterials. This particularly improves their mechanical behavior. Carbon nanotubes are synthesized 
and added to conventional polymer scaffolds to promote and guide tissue growth and regeneration. 
Today, a broad variety of nanostructured materials are developed such as particles, spheres, tubes, fibers, 
and dendrimers [182–184]. Additionally, nanocomposites, nanosurfaces, and nanosphere-immobilized 
biomaterials have gained increasing interest in regenerative medicine due to their ability to mimic the 
extracellular matrix (ECM). Nanomaterials have been intensively studied in the last decade for their use 
in tissue engineering. Material synthesis, characterization and in vitro analysis of nano-based scaffolds 
for tissue engineering applications are reviewed by Wang and co-workers [185]. 
Nanotechniques developed in the past decade include electrospinning and various rapid prototyping 
methods used for 3D scaffold design [186–188]. Three dimensional printing, fused deposition modelling 
(FDM), stereolithography (SL), selective laser ablation (SLA), and selective laser sintering (SLS)  
are considered to be the most promising techniques for smart scaffold fabrication delivering tailored 
three-dimensional scaffold architectures and nanostructured surfaces [174,189,190]. In particular, 
scaffolds with a controllable interconnected pore network are available via rapid prototyping 
technologies, which allows for improved cell migration and nutrient exchange. Electrospinning provides 
fibrous scaffolds, mimicking the dimension and topology of ECM fibers. Filaments can be formed on the 
nanometer scale used as medical membranes and scaffolds for tissue engineering. Sitharaman and  
co-worker reported the preparation and investigation of porous 3D printed scaffolds based on 
functionalized polyesters for tissue engineering [191]. Applications in tissue engineering are mainly 
focused on utilization of nanomaterials to improve mechanical properties of the scaffolds. Nanofibers are 
prepared via electrospinning, phase separation, or self-assembling techniques. Biodegradable polymer 
nanofibers mimic the nanofibrillar structure of ECM. The nanoscaled collagen fibrillar structure  
(50–500 nm in diameter) has been found to enhance cell-matrix-interactions [187]. Lim studied 
micropatterning by femtosecond laser ablation of electrospun nanofiber tissue scaffolds based on 
composites of poly(caprolactone) and gelatin [192]. Nanostructured mesoporous silicon can be used for 
discriminating in vitro calcification of electrospun scaffold composites [193]. Another approach 
combines freeze-drying and foaming techniques to generate highly porous 3D scaffolds [194]. 
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5.2.2. Network Formation via Polymer Cross-Linking 
In 1998, Gagnieu registered a patent for cross-linking techniques of collagen derivatives and their 
utilization as biomaterials [195]. A decade later, Zeugolis and co-workers reported a study of a wide 
range of cross-linking approaches, including chemical, physical, and biological methods regarding the 
influence of cross-links on the properties of resulting collagen structures [196]. Structural evaluation 
revealed a closely packed inter-fiber structure independent of the cross-linking method employed. 
Thermal properties were dependent on the cross-linking method and closely matched native  
tissues. Many efforts are being made to improve the preparation of three-dimensional networks used as 
scaffolds for tissue engineering. However, the generation of tailor-made 3D polymer networks with 
well-defined structure and adjusted chemical and physical properties is still a challenge for material 
scientists. Beside crucial requirements for scaffold materials, there are further special needs dependent 
on the specific application, e.g., the mechanical scrape strain of polymers used in wound assay models 
and the chemical resistance in special cell culture conditions [110,197]. The creation of a discrete 
polymer network would be a possible approach to influence those properties. 
In terms of their 3D structure, collagens are physically cross-linked co-polymers. Dipole forces and 
hydrogen bonds cause a natural helical network. The formation of natural cross-links is based on 
enzymatic reactions by lysyloxidase [198,199]. In addition, further intra- and intermolecular cross-links 
can be developed [200]. Intramolecular diagonal cross-links are formed by spontaneous reaction of 
adjacent aldehyde groups via aldol condensation reactions [201]. In contrast, intermolecular cross-links 
are formed by reactions of the ε-amino groups of certain amino acids (e.g., lysine or hydroxyl lysine). 
Besides the naturally occurring covalent cross-linking, artificial chemically induced cross-linking 
can be performed to modify collagens for cell culture experiments. When collagen comes into contact 
with water, the water is bound either as hydrate or capillary water. Excessive bulking of collagen 
layers in water leads to destructions of the compounds [202–204]. To improve the resistance against 
humidity, chemical modification of side groups (e.g., ε-amino groups of lysine and hydroxyl lysine, 
carboxyl groups of asparagine and glutamine acid) are performed resulting in cross-linked networks. In 
the following paragraphs, the most frequently used cross-linking methods are discussed more in detail: 
Cross-linking via chemical reagents or enzymes, via radiation (UV, gamma or electron beam), or 
thermal treatment. 
Crosslinking by chemical reagents: The majority of cross-linking reactions are performed via  
amino and amide groups. In rare cases, guanidine groups participate in the formation of a cross-linking 
bond [205–210]. Alternatively, bonds are formed between free carboxylic groups—here the reagent is 
not embedded in the collagen matrix reagent [211]. The reaction mechanism of the cross-linking reaction 
initiated by formaldehyde is shown in Figure 4A [200,212]. This formaldehyde-protein-reaction depends 
strongly on the experimental conditions and is not specific to lysine [212].  
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Figure 4. Cross-linking reactions. (A) Cross-linking via formaldehyde. In the first step 
amino groups of collagen (e.g., in lysine entities) react with formaldehyde to form an 
aminomethylol-derivative. In the second step, a diagonal cross-link is formed by reaction 
of the aminomethylol-derivative with an acid amide; (B) Cross-linking via glutaraldehyde. 
Reaction of amino groups of two collagen molecules (e.g., in lysine entities) with 
glutaraldehyde leads to diagonal crosslinking of collagen molecules; (C) Cross-linking via 
hexamethylene diisocyanate. Hexamethylene diisocyanate can react with amino groups to 
crosslink collagens; (D) Cross-linking via enzymes. During enzymatic cross-linking with 
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Another cross-linking mechanism involving two free amino groups and glutaraldehyde is shown  
in Figure 4B [213]. Unfortunately, this cross-linking reaction mechanism may cause subsequent 
hydrolysis reactions. Analogue to the mechanism shown in Figure 4A, hexamethylene diisocyanate 
leads to cross-linking by reacting with two amino groups [214]. The formation of amid bonds between 
free carboxyl- and amino groups is shown in Figure 4C. In addition, cross-linking can be reached via 
acyl-azides or aqueous solution of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide [211,215]. 
Formaldehyde and glutaraldehyde are the most commonly used compounds. Glutaraldehyde shows a 
higher activity with increasing pH values, finding a maximum at pH 8 [216]. In contrast, formaldehyde 
exhibits an increased activity at lower pH values (<6.5), an essential advantage considering that most 
collagens exhibit pH value in the range between 2.5 and 3.0. Decreasing cross-linking velocity could 
result in unstable, partially reversible compounds [200,206,207]. Cross-linking of glutaraldehyde is not 
only fast, the resulting products are also significantly more stable. Similar network qualities in terms of 
mechanical stability are found in collagen fibers treated with hexamethylene diisocyanate [216]. The 
cytotoxicity is lower for the acyl-azid method in comparison to the glutaraldehyde method. The use of 
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide with supporting agent N-hydroxysuccinimide (NHS) 
is a cell compatible cross-linking method. NHS takes part in the activation and not in the cross-linking. 
This discloses cytotoxic effects. The so improved collagen scaffolds are primarily used for cell 
culturing [214]. The relatively fast activation is not applicable in aqueous solutions, commonly  
used to prepare films and scaffolds [196]. Economic and technical reasons hamper the application  
of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide for cross-linking reactions [217]. Marzec and 
Pietrucha studied collagen cross-linking with hyaluronic acid (HA) to be used for scaffold  
fabrication [218]. Resulting networks were investigated by the dielectric spectroscopy over a wide 
range of temperatures and provided detailed information on molecular interactions in cross-linked 
collagen. Cross-linking and grafting of the collagen film by HA is effective not only in slowing down 
the biodegradation rate, but also in optimizing the dielectric properties of these systems. 
Crosslinking by enzymes is a very efficient, nontoxic method to stabilize collagen matrices. The 
most common enzyme for cross-linking reactions is transglutaminase (TGM), which is commercially 
used in food industry to improve the texture, emulsion properties, firmness, and elasticity of protein 
containing food like yogurt, fish, or meat [219]. Water resistance and tensile strength of 3D networks 
can be improved using TGM [220]. In addition, TGM is used for modification of galantine [221]. 
Stachel et al. describes the improvement of biocompatibility of medical implant materials in 
mammalian host bodies by TGM cross-linking of raw collagen [219]. Claims are made regarding 
improvements in cell adhesion, proliferation, and differentiation. The transglutaminase catalyzes an 
acyl-transfer reaction between a γ-carbamide group of a protein bonded glutamine and an ε-amino 
group of a protein bonded lysine resulting in the formation of intermolecular or intramolecular  
ε-(γ-glutamyl)lysine isopeptide bonds as shown in Figure 4B [219,222]. However, disadvantages of 
this treatment are rather long reaction times (between 6 to 8 h) and the complex inactivation. 
Crosslinking by irradiation: The different beam induced cross-linking methods have clear 
advantages towards chemical cross-linking methods. First, there is no need for additional chemicals or 
supporting agents. The combination of cross-linking and simultaneous sterilization makes these 
methods especially interesting for medical and biological applications. To realize beam sterilization, a 
minimum dose of 25 kGy is needed [223]. Thus, the collagen composition to be cross-linked and  
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the radiation dose must be scaled and adjusted. High intensities can cause fragmentation and 
denaturation [224]. In general, three different types of irradiation treatment of collagen are established: 
UV radiation, gamma ray treatment, and electron beam radiation. The treatment with UV rays is based 
on the creation of free radicals in aromatic residuals of tyrosine and phenylalanine. Cross-linking 
reactions occur between those radicals limited by the rather low amount of aromatic amino acids in 
collagen [224]. Collagen consists of specific chemical units, which show absorption in the near  
(315–380 nm, UV-A) and middle UV range (280–315 nm, UV-B), whereas the aromatic amino acids 
absorb in the far UV range (280–200 nm, UV-C). Treatment times between 15 and 30 min are 
reported. The effective radiation depth is limited to a few nanometers and therefore to the immediate 
surface [225]. Photochemical cross-linking with riboflavin was investigated for the treatment of 
keratoconus, a degenerative disorder of the eye in which structural changes of the cornea cause a 
decrease in thickness [226]. Very recently, Hayes and colleagues published the effect of riboflavin/UV 
collagen cross-linking therapy on the structure and hydrodynamic behavior of the ungulate and rabbit 
corneal stroma [227]. 
Gamma ray treatment (60Co-source) of collagen leads to cross-linking by imine and aldol bonds, 
which are generated by oxidative deamination. In addition, covalent links are formed from emerging 
free radicals [195,228]. 
Crosslinking by Electron Beam Radiation represents an innovative method for treatment and 
sterilization of biomaterials. In contrast to gamma rays (electromagnetic waves), electron beam 
provides a particle radiation [228]. In general, the effect of electron beam irradiation on matter is rather 
complex. Given that radicals are produced, this method can be used for the modification of polymers, 
particularly polymer surfaces and treatment of biological materials, summarized in Figure 5. Besides 
cross-linking and degradation, which are in most cases the desired outcomes of electron beam 
treatment, further processes can take place depending on the chemical feature of the polymer, involved 
process gases, and other energy depending factors [229,230]. Scission of the peptide bonds in collagen 
occurs during electron beam treatment under standardized conditions using inert gas atmosphere. 
Although electron beam treatment can lead to instability of the helical structure, the helix can  
be maintained if the links are as close as possible to the scission position. This effect is observable 
when high radiation doses and temperature above the melting temperature of collagen in a nitrogen 
atmosphere are used, resulting in intermolecular covalent cross-linking. The cross-linking density 
increases with increasing radiation dose [231]. The disadvantage in comparison to the gamma ray 
treatment is the lower depth of a few μm up to a few mm [223]. However, this is overbalanced by the 
advantages of a disengageable radiation source, short treatment times of few minutes, an easy adaption 
of treatment parameters, and a lower impairment of biomechanical properties of the corresponding 
biological network [232]. Besides the irradiation energy, an important parameter is the dose absorbed 
by the material. The wide range of applications of electron beam treatment is shown in Table 1. 
J. Clin. Med. 2014, 3 68 
 
 
Figure 5. Energy sources and their application for polymeric and biological systems. 
Chemical reaction, UV-light, gamma rays, electron beam or enzymatic processing are 
valuable tools for the modification of polymeric materials. Hereby, miscellaneous, partially 
contrary effects are observed including cross-linking reactions. For biological applications, 
sterilization, disinfection and pasteurizing effects are described. 
 
 
Table 1. Selected industrial applications of irradiation processing [233–236]. 
Irradiation target Net effect Dose range (kGy) 
Food Cold pasteurization 0.3–30 
Medical disposable items Sterilization 10–60 
Cellulose and derivates Degradation 5–50 
Polymer coatings Curing 30–160 
Polyolefin foams Crosslinking 40–80 
Heat-shrinkable materials Memory imparted 75–250 
Soft materials (especially rubber) Cross-linking/Vulcanization 80–400 
Fluoropolymers Degradation 500–1500 
Gemstones Coloration >10,000 
The use of electron beam technology for the modification of polymeric surfaces or for the linking of 
surface modified layers to organic support structures is represented in several examples [237,238]. 
However, systematic investigations of the electron beam treatment in modifying biological polymer 
materials like collagen are rarely published in a well-defined manner. The predominant process in the 
application of electron beam treatment of collagen-based substrates is described as radically initiated 
cross-linking [231]. Investigations regarding the detailed mechanism of the cross-linking reaction are not 
yet available. One can assume that network formation originates in radical creation in peptide-based 
structures, which is sufficiently described for UV- and gamma ray treatment [195,206,239–241]. 
Furthermore, bond scissions are observed in addition to cross-linking [242]. Investigations of co-cultures 
of hepatocytes and endothelial cells on electron beam structured poly(N-isopropylacrylamide) 
substrates are published [243]. Degradation is described as predominantly for cellulose based 
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biopolymers [244,245]. On the other hand, natural rubber (Guttapercha, poly(1,4-cis-isoprene) and 
synthetic poly(1,4-cis-isoprene)) are well cross-linkable to achieve elastomers using electron beam 
treatment without cross-linking agents [244]. The electron beam treatment of biological polymers and 
co-polymers based on PLA and PHB can either achieve cross-linking or degradation, depending on the 
reagent [233,245–252]. However, detailed knowledge concerning the effect of electron beam treatment 
on the structure and properties of the treated polymers is predominantly known from investigation of 
synthetic polymers [234,235,244,246]. Polymers with either secondary or allylic bound carbon atoms 
in their polymer chain, like polyethylene, polybutadiene, polyisoprene, or silicones, tend to undergo 
cross-linking reactions. In contrast, polymers with tertiary carbons atoms in the polymer chain, like 
polypropylene, polymethylacrylate, polyisobutylene, polytetrafluoroethylene, or cellulose derivates, 
tend to undergo degradation by chain scission. When cross-linking dominates in contrast to bond 
scissions, the degree of cross-linking points is proportional to the absorbed dose and can be evaluated 
using relations between the degree of cross-linking and physical or mechanical properties [236,253]. 
However, it should be considered that the density of radicals is lower in comparison to chemical  
cross-linking reactions. The relative absorbed dose is commonly described in dependency of the area 
density of the polymer [254]. In summary, electron beam irradiation has considerable advantages 
compared to chemical based methods, beam induced UV, and gamma ray treatments including 
variable effective depth, short treatment times, disengageable radiation source, low heat emission, 
applicability at room temperature, no need for cross-linking agents, and sterilization effect [255,256]. 
This treatment method is well-established in medical engineering. A subsequent sterilization of the 
modified polymer substrate using steam pressure sterilization or ethylene oxide is not necessary. Thus, 
the technologically versatile process of electron beam treatment has the potential for innovative 
modification of cell culture materials, and fulfills the need for a simple commercial method with a 
limited number of procedural steps for modification and sterilization [256,257]. 
Cross-linking by thermal treatment is mainly realized via the so-called dehydrothermal method, 
which entails eliminating water in a stepwise process under vacuum in temperatures around 100 °C. 
Subsequently, it has been observed that a reformation of amid bonds via reaction of carboxyl and 
amino groups can lead to a cross-linked collagen matrix. Hiraok and colleagues investigated collagen 
sponges mechanically reinforced through the incorporation of poly(glycolic acid) fiber [258]. They 
prepared collagen-PGA dispersions that were freeze-dried, followed by dehydrothermal cross-linking 
to obtain collagen sponges incorporating PGA fiber to various extents. By scanning electron 
microscopy observation, the collagen sponges exhibited isotropic and interconnected pore structures 
with an average size of 180 μm, irrespective of PGA fiber incorporation. As expected, PGA fiber 
incorporation enabled the collagen sponges to significantly enhance their compression strength. 
6. Summary of Scaffolds for Vascular Grafts 
The target goal of tissue engineered vascular grafts and conduit vessels are systems that perfectly 
mimic natural vessels, while avoiding immunological rejection. Tremendous efforts are made to 
improve scaffold materials in terms of architecture, topography, and bioactivity. Primary attention is 
given to produce appropriate three-dimensional porous networks using conventional or nano-based 
fabrication methods. Regarding conventional methods, chemical, physical, and biological cross-linking 
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methods can be used to generate scaffolds that closely match native tissues. In particular, the 
technologically versatile process of cross-linking via electron beam treatment has the potential for 
innovative modification of cell culture materials, and fulfills the need for a simple commercial  
method with a limited number of procedural steps for modification and sterilization. High expectations 
exist for the development of artificial vessel replacements using nanomaterials and rapid  
prototyping fabrication technologies. Most prominent candidates are electrospinning and laser printing 
technologies. Nanotechnology can provide an alternative platform to develop materials of higher 
mechanical strength, enhanced functionality, and resorbability for improving the quality of tissue 
engineered vascular grafts [259,260]. The future of new tissue engineered biomaterials depends on an 
enhanced knowledge and better understanding of both the structure-property relationships of the 
targeted scaffolds, and the most significant inter- and intramolecular, cellular, and tissue interactions. 
Tailor-made and appropriately characterized scaffold materials including hierarchically structured 3D 
networks and hybrid materials with enhanced bulk and surface properties will become a major 
preoccupation for successful scaffold development [156]. In particular, biomimetic and bioinspired 
multifunctional composite and hybrid materials with well-defined nanostructure and nanotopography 
that elicit the desired cellular and tissue response will be the primary task for the next generation of 
artificial substitutes. In addition to potential clinical applications, such engineered biomaterials will 
add fundamental contributions to basic research, including better understanding of the interactions of 
materials with living cell systems [260]. 
7. Conclusions 
Cardiovascular diseases are the main cause of death in industrialized countries and can be expected 
to increase in the future due to an increase life expectancy of the population combined with a sedentary 
lifestyle and an increase in adipositas. This leads to the increasing need for treatment methods for 
vascular diseases, starting with lifestyle changes and drug treatments, to new methods such as tissue 
replacement strategies. Within the last decade, high hopes rely increasingly on the development of 
artificial vascular grafts which have shown major improvements due to innovations, both in cell 
culture and material science. Numerous new approaches have been published and patented using 
combinations of stem cell-based tissues on tailor-made biomaterials tested in small and even large 
animal models already, thus passing to some extent the preclinical phase. However, none of them have 
entered clinical trials phases until now. 
In spite of these promising developments, tissue engineering of vascular grafts still has major 
problems to solve. The potential success strongly depends on the availability of an appropriate cell 
type for the graft material. All possible kinds of cells tested at the moment range from fully 
differentiated vascular tissue cells to stem cells with the full range of plasticity, indicating that the best 
solution has to be found yet. 
Scaffold design for cell engineering is targeted to mimic the native cell microenvironment. Thus, a 
combination of biological, biochemical, physical, and mechanical interactions has to be adjusted. 
Within the last two decades, a widespread variety of scaffold materials and fabrication methods have 
been addressed, including natural and synthetic materials. Thus, both types allow the use of technically 
well-established fabrication methods and provide scaffolds with the desired mechanical properties. 
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However, the resulting scaffolds, in particular the scaffold surface, must be modified and bio-activated 
to mimic the biochemical microenvironment of cells. Natural materials exhibit a closer analogy to the 
biochemical microenvironment. However, their use requires highly sophisticated production methods 
and, if processed with technical fabrication methods, additional crosslinking or reinforcement to gain 
scaffolds of sufficient mechanical stability. The use of cell expressed ECM and its immobilization on 
carriers comes as close as possible to the natural microenvironments and is therefore a promising path 
towards a well-founded understanding of the metabolism of the respective cell type. In the future, a 
successful application of vascular grafts in humans will combine tightly monitored and orchestrated 
procedures with well-tailored biomaterial. 
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